Otonomy Inc. (OTIC) had a rough trading day for Tuesday December 18 as shares tumbled 5.02%, or a loss of $-0.11 per share, to close at $2.08. After opening the day at $2.21, shares of Otonomy Inc. traded as high as $2.23 and as low as $2.05. Volume was 204,374 shares over 1,012 trades, against an average daily volume of n/a shares and a total float of 30.63 million.
As a result of the decline, Otonomy Inc. now has a market cap of $63.71 million. In the last year, shares of Otonomy Inc. have traded between a range of $6.45 and $2.16, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere’s disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity is primarily operates through the region of United States.
Otonomy Inc. is based out of San Diego, CA and has some 53 employees. Its CEO is David A. Weber.